PD-L1promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy
| Autor: | Verena Sailer, Emily Eva Holmes, Jörn Dietrich, Dimo Dietrich, Heidrun Gevensleben, Diane Goltz, Glen Kristiansen, Jörg Ellinger |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Male
PD-L1 0301 basic medicine Oncology Biochemical recurrence medicine.medical_specialty medicine.medical_treatment B7-H1 Antigen Disease-Free Survival 03 medical and health sciences Prostate cancer 0302 clinical medicine Predictive Value of Tests Prostate Internal medicine Biomarkers Tumor Humans Medicine Promoter Regions Genetic prognostic biomarker Prostatectomy DNA methylation business.industry Proportional hazards model Hazard ratio Prostatic Neoplasms Middle Aged Prognosis prostate cancer medicine.disease Surgery Treatment Outcome 030104 developmental biology medicine.anatomical_structure 030220 oncology & carcinogenesis Predictive value of tests Biomarker (medicine) business Follow-Up Studies Research Paper |
| Zdroj: | Oncotarget |
| ISSN: | 1949-2553 |
| DOI: | 10.18632/oncotarget.13161 |
| Popis: | // Heidrun Gevensleben 1, * , Emily Eva Holmes 1, * , Diane Goltz 1, * , Jorn Dietrich 2 , Verena Sailer 3, 4 , Jorg Ellinger 5 , Dimo Dietrich 1, 2, ** , Glen Kristiansen 1, ** 1 Institute of Pathology, University Hospital Bonn, Bonn, Germany 2 Department of Otolaryngology, Head and Neck Surgery, University Hospital Bonn, Bonn, Germany 3 Weill Cornell Medicine of Cornell University, Department of Pathology and Laboratory Medicine, New York, NY, USA 4 Weill Cornell Medicine of Cornell University, Englander Institute for Precision Medicine, New York, NY, USA 5 Department of Urology, University Hospital Bonn, Bonn, Germany * These authors have contributed equally to this work ** These authors are joint senior authors of this work Correspondence to: Dimo Dietrich, email: dimo.dietrich@gmail.com Keywords: PD-L1, prostate cancer, DNA methylation, prognostic biomarker Received: August 05, 2016 Accepted: October 13, 2016 Published: November 07, 2016 ABSTRACT Background: The rapid development of programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors has generated an urgent need for biomarkers assisting the selection of patients eligible for therapy. The use of PD-L1 immunohistochemistry, which has been suggested as a predictive biomarker, however, is confounded by multiple unresolved issues. The aim of this study therefore was to quantify PD-L1 DNA methylation ( mPD-L1 ) in prostate tissue samples and to evaluate its potential as a biomarker in prostate cancer (PCa). Results: In the training cohort, normal tissue showed significantly lower levels of mPD-L1 compared to tumor tissue. High mPD-L1 in PCa was associated with biochemical recurrence (BCR) in univariate Cox proportional hazards (hazard ratio (HR)=2.60 [95%CI: 1.50-4.51], p=0.001) and Kaplan-Meier analyses (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|